L-Lysine Hydrochloride, L-Arginine Hydrochloride — Drug Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

4 Recruiting

5 Completed trials

6 Sponsors

13 Countries

Phase III

Phase II

Phase I/II

Phase I (Other)

Phase III: 4 Phase II: 3 Phase I/II: 1 Phase I (Other): 1

Oversight events:

1 serious breach 6 temporary halts 1 unexpected event across 3 trials

View oversight register →

Indications tested

Gastroenteropancreatic neuroendocrine tumour disease 4 Neuroendocrine tumour 3 Peripheral primitive neuroectodermal tumour of soft tissue 1 Central nervous system neoplasm 1 Lymphoma 1 Gastrointestinal stromal tumour 1 Neuroblastoma 1 Rhabdomyosarcoma 1 Ewing's sarcoma 1 Neoplasm malignant 1

Sponsors using this IMP

ITM Solucin GmbH 3 Advanced Accelerator Applications 2 Grupo Espanol De Tumores Neuroendocrinos 1 Institut Regional Du Cancer De Montpellier 1 Karolinska University Hospital 1 Pentixapharm AG 1

All trials

9 total

A trial to determine the dose, and evaluate the safety and pharmacokinetics of lutetium Lu 177 edotreotide in children with somatostatin rec… Recruiting

2024-512831-66-00 Phase I (Other) 3 countries ITM Solucin GmbH
A study to examine the safety, tolerablity, body distribution and efficacy of [90Y]Y-PentixaTher therapy in CNS lymphoma patients. Recruiting

2024-512097-98-00 Phase I/II 1 country Pentixapharm AG
177Lu-edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus Recruiting

2022-502154-13-00 Phase III 4 countries Grupo Espanol De Tumores Neuroendocrinos
STUDY TO ASSESS THE SCHEMAS OF RETREATMENT WITH LUTATHERA® IN PATIENTS WITH NEW PROGRESSION OF INTESTINAL WELL-DIFFERENTIATED NEUROENDOCRINE… Recruiting

2024-511001-28-00 Phase II 1 country Institut Regional Du Cancer De Montpellier
A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma LuDO-N Ended

2023-503684-42-00 Phase II 6 countries Karolinska University Hospital
Lutetium (177Lu) Edotreotide versus Best Standard of Care in Well-differentiated Aggressive Grade 2 and Grade 3 Gastroenteropancreatic Neuro… Ended

2024-510812-64-00 Phase III 5 countries ITM Solucin GmbH
Study to evaluate safety and dosimetry of Lutathera in adolescent patients with GEP-NETs and PPGLs. Ended

2023-507444-37-00 Phase II 3 countries Advanced Accelerator Applications
A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in combination with best supportive … Ended

2023-507443-10-00 Phase III 5 countries Advanced Accelerator Applications
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) Ended

2023-510444-21-00 Phase III 9 countries ITM Solucin GmbH

Showing 1–9 of 9 trials

← All drugs A–Z